Skip to content

2008 Weight Loss, Protein and Bone Density study

A randomised study to investigate the effect of high and normal protein content in weight loss diets on bone density in overweight post menopausal women.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12608000229370
Acronym
BD
Enrollment
200
Registered
2008-05-02
Start date
2008-04-14
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

A 104 week weight loss study of either: A high protein diet (35% of calories as protein), low saturated fat (<10%), low total fat (<30%), OR A normal protein diet with a protein level of 15-20% of calories, low saturated fat (<10%), low total fat (<30%). Both diets will contain 5000-6000KJ

Sponsors

CSIRO Human Nutrition
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

• Female, post menopausal • Aged between 40-70 years • Body Mass Index (BMI) greater than 27, but a maximum weight of 140kg • Participants must understand the procedures involved and agree to participate in the study by giving full informed, written consent

Exclusion criteria

• Body mass index (BMI) less than 27 • Taking antiresorptive agents –including Hormone Replacement Therapy • Vitamin D and/or parathyroid hormone (PTH) and/or serum calcium levels outside the normal range when tested at baseline. If vitamin D is less than 60 and PTH is normal participants will continue in the study but if PTH is also elevated then the participant will be withdrawn and referred to their GP for active treatment. • Taking agents affecting calcium and bone metabolism such as calcium supplements, steroids or diuretics. • Bone density in the osteoporotic density range (total hip 2 SD below normal) or a history of low trauma peripheral or spinal fracture (with density <1 SD below normal) as assessed at the baseline examination. • Have a malignancy, or a history of metabolic disease such as liver, renal, unstable cardiovascular, respiratory or gastrointestinal disease. • Have high uncontrolled hypertension (resting recumbent Blood Pressure >160/100 mmHg). Once controlled on medication the participant can enter the study • History of heavy alcohol consumption (> 5 standard drinks/day) • Unwilling to be randomized to either trial group • Extended absences due to travel or other commitments • Unable to comprehend or cope with study requirements • At the commencement of the study bone density at the hip, spine and forearm will be measured. Those women in the osteoporotic density range (very low bone density ) at the first examination will not be eligible to participate but will be referred back to their general practitioner for specific treatment. Those with osteopenia (moderately low bone density) and no fractures will be able to continue in the study if they wish.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 22, 2026